Friday, July 31, 2026

Tesla Falls 2.84% After Trump’s Tariff News Drags Down EV Stocks

U.S. stock market drops after Trump's tariff announcement, impacting Tesla and other EV stocks despite earlier gains from bullish forecasts.

Meet Hyundai’s Latest Electric Marvel: The Casper Electric SUV!

At the Busan Mobility Show, Hyundai Motor...

Is VRN110755 the Future of Non-Small Cell Lung Cancer Treatment? Find Out!

Voronoi's VRN110755 for NSCLC receives approval for clinical trial modifications, expanding to a Phase 1b/2 trial across multiple regions.

Tag: Korea

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Depression Linked to Up to 2.4-Fold Higher Risk of Fatty Liver Disease in Young Adults, Study Finds

A South Korean study reveals young adults with depression face double the risk of fatty liver disease compared to those without.

Exclusive: GC Biopharma Seeks First Phase 2 Trial for Homegrown mRNA Vaccine This Week

GC Biopharma advances to Phase 2 of South Korea's mRNA vaccine program, aiming for late-stage trials after Phase 1 completion.

Patients Travel Overseas for Cell Therapies—South Korea Moves to Lower Barriers to Treatment

South Korean patients seek stem cell therapies abroad due to limited options at home, despite high costs and uncertain efficacy.

Celltrion Group’s 2 Trillion KRW Investment: What It Means for Global Bio Manufacturing by 2032

Celltrion Group plans a 2 trillion KRW investment to enhance production capacity and establish a leading position in global biotech.

Humanoid Robots Will Be Driven by Data, Not Just AI Models, Omdia Says: South Korea Could Become Alternative to U.S.-China Supply Chain

Data collection and ecosystem development are crucial for the humanoid robot industry's success, with South Korea as a potential third supply chain.

South Korea Eases Phase 3 Trial Requirements for Biosimilars Following U.S. and EU… Early Data Becomes Key Battleground

South Korea's MFDS eases Phase 3 trial requirements for biosimilars, aligning with global trends, enhancing early comparability importance.

U.S. pharmaceutical companies’ China clinical trial security probe to conclude this week… Could biotech rivalry intensify?

A U.S. investigation into pharmaceutical trials in China may reshape global biotech strategies, impacting South Korean firms.

Belvarafenib: The Promising New Targeted Cancer Drug for NRAS Mutant Melanoma

Hanmi Pharmaceutical presents Belvarafenib's phase 2 trial for NRAS mutant melanoma at KCA 2026, targeting unmet medical needs.

Korea’s First CAR-T Therapy Clears Initial Reimbursement Hurdle, With First Prescriptions Expected in October

South Korea's first CAR-T therapy, Rimkato, moves closer to national health insurance reimbursement, with commercialization expected by year-end.

Hospitals Fuel South Korea’s Stem Cell Treatment Boom, but Experts Call for Stronger Patient Safeguards

South Korea's stem cell therapies expand rapidly, but lack regulation and clinical evidence, raising patient concerns about treatment choices.

Seoul Asan Medical Center Surpasses 3,000 Adult ECMO Cases, With 65% Successfully Weaned From Life Support

Seoul Asan Medical Center has performed over 3,000 ECMO procedures, achieving a 65% weaning success rate for critically ill patients.

2026 Residency Report: Why Reduced Working Hours Aren’t Improving Mental Health for Asian Doctors

Despite reduced working hours, medical residents face worsening mental health, highlighting a need for better training and support systems.

China’s Fosun Pharma invests $27.5 million in AriBio, boosting optimism for Korean Alzheimer’s drug

Fosun Pharma invests $27.5 million in South Korea's AriBio, boosting its Alzheimer’s drug development and global commercialization efforts.

Coupang vs. South Korea: Did the National Intelligence Service Really Intervene in Data Recovery?

The U.S. House report alleges Coupang faced discriminatory treatment by South Korea's NIS, raising concerns over data recovery practices.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.